Skip to main content
Peter Marks, MD, Hematology, New Haven, CT

PeterWayneMarksMD

Hematology • New Haven, CT

Associate Professor of Medicine, Yale University

Join to view full profile

Are you Dr. Marks?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 56 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Peter Marks, MD is a hematologist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut, New Jersey, and Massachusetts. He is an Associate Professor of Medicine at Yale University.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1996
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1991 - 1993
  • New York University School of Medicine
    New York University School of MedicineClass of 1991

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1992 - 2025
  • NJ State Medical License
    NJ State Medical License 2004 - 2025
  • CT State Medical License
    CT State Medical License 2006 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow (FACP) American College of Physicians, 2011

Publications & Presentations

PubMed

Press Mentions

  • $3.5M Gene Therapy for Hemophilia Gets FDA Approval
    $3.5M Gene Therapy for Hemophilia Gets FDA ApprovalNovember 22nd, 2022
  • FDA Approves First Gene Therapy for Hemophilia B
    FDA Approves First Gene Therapy for Hemophilia BNovember 22nd, 2022
  • FDA Approves New Treatment for Adults with Relapsed or Refractory Large-B-cell Lymphoma
    FDA Approves New Treatment for Adults with Relapsed or Refractory Large-B-cell LymphomaFebruary 5th, 2021
  • Join now to see all

Professional Memberships

Dr. Peter Marks, Dr. Peter Marks, MD, Dr. P Marks, Dr. Peter Wayne Marks